Search Orphan Drug Designations and Approvals
-
| Generic Name: | DNA, (Cm-Gm-Gm-Gm-G-T-G-T-G-G-G-T-T-C-G-T-C-G-T-T-A-G-C-T-T-G-A-T-T-T-G-G-C-A-G-C-Um-Gm-Cm-Cm-(5'->3')-dT), 5'-ester with (29S)-29-(tert-butoxycarbonyl)-1-((hydroxyphosphoryl)oxy)-8,17,26,31-tetraoxo-10,13,19,22-tetraoxa-7,16,25,30-tetraazaoctatetracontan-48-oic acid |
|---|---|
| Date Designated: | 11/03/2022 |
| Orphan Designation: | Treatment of Osteogenesis Imperfecta |
| Orphan Designation Status: | Designated |
| FDA Orphan Approval Status: | Not FDA Approved for Orphan Indication |
| Sponsor: |
Aptacure Therapeutics Limited M13, 1/F, Unit 101-103, Building 15 of Hong Kong Science Park No. 15 Science Park West Avenue Pak Shek Kok, New Territories Hong Kong The sponsor address listed is the last reported by the sponsor to OOPD. |
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-







